Tumor-specific but not nonspecific cell-free circulating DNA can be used to monitor disease response in lymphoma.
Recently, nontumor specific circulating DNA was shown to be elevated in a broad range of lymphomas, implicating a role as a potential biomarker. Epstein-Barr virus' (EBV) presence within a proportion of lymphomas implies EBV-DNA has potential as a lymphoma-specific disease response biomarker. However, application would be restricted to EBV-associated lymphomas. Neither detailed comparison has been performed of lymphoma-specific versus nonspecific DNA as disease response biomarkers nor have the kinetics of circulating DNA during treatment been established, and the optimal methodology remains unknown. We prospectively evaluated DNA levels and clinical response of 63 lymphoma patients. DNA was measured in paired serum, plasma, and cell samples at five predetermined time-points taken prior, during and following treatment. Both cell-free (c-f) circulating EBV-DNA (in EBV-associated lymphoma) and nonspecific c-f DNA levels (in all lymphomas) were elevated and discriminatory at presentation compared to healthy controls. Nonspecific c-f DNA was significantly associated with baseline serum lactate dehydrogenase. Within EBV-associated lymphomas at presentation, there was a strong correlation between specific and nonspecific circulating c-f DNA (r = 0.9, P < 0.0001). However, only c-f EBV-DNA correlated with clinical/radiological response. In addition, c-f EBV-DNA, and not nonspecific c-f DNA, provided an early marker of relapsed and refractory disease. Serum versus plasma, and single versus multiple-copy EBV-gene targets were equivalent. Lymphoma-specific DNA is a disease response biomarker; however, nonspecific DNA reflected neither lymphoma-specific DNA nor therapeutic response. Lymphoma disease response can be monitored by blood tests, but new lymphoma-specific biomarkers need to be identified to broaden applicability.
Clinical Immunohaematology Laboratory, Queensland Institute of Medical Research, Brisbane, Australia.
Kimberley
K
Jones
Jamie P
JP
Nourse
Colm
C
Keane
Pauline
P
Crooks
David
D
Gottlieb
David S
DS
Ritchie
Devinder
D
Gill
Maher K
MK
Gandhi
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D004273:DNA, Neoplasm / Q000097:blood*; D004279:DNA, Viral / Q000097:blood*; D020031:Epstein-Barr Virus Infections / Q000097:blood*; D005260:Female; D004854:Herpesvirus 4, Human / Q000235:genetics*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000737:chemistry; D008223:Lymphoma / Q000097:blood* / Q000145:classification / Q000188:drug therapy / Q000821:virology; D008297:Male; D008875:Middle Aged; D010949:Plasma; D012680:Sensitivity and Specificity; D044967:Serum; D016896:Treatment Outcome; D019562:Viral Load; D014766:Viremia / Q000097:blood; D055815:Young Adult
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D004279:DNA, Viral